ENXTBR:UCBPharmaceuticals
Assessing UCB’s (ENXTBR:UCB) Valuation As Korean Patient Access Efforts Gain Traction
Why UCB’s Korean access push matters for ENXTBR:UCB shareholders
UCB (ENXTBR:UCB) is in focus after its Korean unit highlighted a renewed push on patient access, following recent reimbursement wins for Bimzelx and Fintepla and preparation for Rystiggo and Zilbrysq.
See our latest analysis for UCB.
The Korean access push lands at a time when UCB’s share price has eased, with a 30 day share price return down 11% and a 90 day share price return down 17.7%, yet its 1 year total shareholder return...